-
-
-
-
-
-
-
Senti Biosciences (SNTI) Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202
-
-
-
-
-
-
-
Senti Biosciences (SNTI) Files $300M Mixed Shelf
-
-
-
-
-
-
-
Senti Biosciences (SNTI) Announces Oversubscribed $37.6 Million Private Placement Equity Financing
-
-
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

